JPRN-UMIN000005690已完成2 期
PhaseII study of gefitinib combined with cisplatin and pemetrexed in patients with advanced non-squamous, non-small cell lung cancer acquired resistance to first line gefitinib monotherapy. - PhaseII study of gefitinib combined with cisplatin and pemetrexed in patients with advanced non-squamous, non-small cell lung cancer acquired resistance to first line gefitinib monotherapy.
Division of Thoracic Oncology, Shizuoka Cancer Center0 个研究点目标入组 30 人开始时间: 2011年6月2日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Impossible cases with protcol defined oral administration. 2) Patients with symptomatic brain metastasis. 3) With active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis,or drug-induced pneumonitis. 4) Thoracic radiation, within 4 weeks, irradiation to other organs within 2 weeks. 5) Uncontrollable pleural or pericardial effusion. 6) Operation within 4 weeks. 7) Active infection. 8) Active concomitant malignancy. 9) Severe drug allergy. 10) Pregnant or breast-feeding woman. 11) Inappropriate patients for this study judged by the physicians.
研究者
相似试验
已完成
3 期
PhaseIII study of gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer with EGFR mutationon small cell lung cancerJPRN-UMIN000000539West Japan Oncology Group200
已完成
不适用
Phase II study of gefitinib combined with carboplatin/pemetrexed for elderly patients with EGFR mutated advanced non-small cell lung cancerJPRN-UMIN000016391Tohoku University Hospital35
已完成
不适用
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42
已完成
2 期
Phase II study of gefitinib therapy inserted by chemotherapy as first line treatment for advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutatioon-small-cell lung cancerJPRN-UMIN000001738Thoracic Medical Oncology, National Cancer Center Hospital33
已完成
2 期
A phase II trial of gefitinib and concurrent radiation therapy for locally advanced non-small cell lung cancer patients harboring sensitive EGFR mutations.on-small cell lung cancerJPRN-UMIN000003274ational Hospital Organization15